Novartis shares jump after positive data in experimental heart treatment
Novartis released results for two of three watched trials in the second half of the year. U.S.-listed shares soared 6% Tuesday to $161.25 on positive study data for an experimental treatment for…
By Catherine Dunn Novartis released results for two of the three trials that Wall Street had been watching for in the second half of the year. U.S.-listed Novartis shares rose 6% on Tuesday to $161.25 after positive study data on an experimental treatment for…